BIOCYTOGEN PHARMA. H YC1 (I54) - Total Liabilities
Based on the latest financial reports, BIOCYTOGEN PHARMA. H YC1 (I54) has total liabilities worth €1.54 Billion EUR (≈ $1.81 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check I54 financial resilience to evaluate the company's liquid asset resilience ratio.
BIOCYTOGEN PHARMA. H YC1 - Total Liabilities Trend (2021–2025)
This chart illustrates how BIOCYTOGEN PHARMA. H YC1's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see BIOCYTOGEN PHARMA. H YC1 balance sheet assets.
BIOCYTOGEN PHARMA. H YC1 Competitors by Total Liabilities
The table below lists competitors of BIOCYTOGEN PHARMA. H YC1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CECEP Techand Ecology&Environment Co Ltd
SHE:300197
|
China | CN¥23.65 Billion |
|
Theravance Biopharma Inc
NASDAQ:TBPH
|
USA | $188.85 Million |
|
Fujian Longma Envi Sanitation
SHG:603686
|
China | CN¥3.36 Billion |
|
Indus Holding AG
XETRA:INH
|
Germany | €1.24 Billion |
|
Foschini Group Ltd
JSE:TFG
|
South Africa | ZAC35.30 Billion |
|
Unilumin Group Co Ltd
SHE:300232
|
China | CN¥5.24 Billion |
|
Shanghai Chuangli Group Co Ltd
SHG:603012
|
China | CN¥3.99 Billion |
|
Wave Life Sciences Ltd
NASDAQ:WVE
|
USA | $71.81 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down BIOCYTOGEN PHARMA. H YC1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See I54 net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BIOCYTOGEN PHARMA. H YC1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BIOCYTOGEN PHARMA. H YC1 (2021–2025)
The table below shows the annual total liabilities of BIOCYTOGEN PHARMA. H YC1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.54 Billion ≈ $1.81 Billion |
-2.02% |
| 2024-12-31 | €1.58 Billion ≈ $1.84 Billion |
-4.96% |
| 2023-12-31 | €1.66 Billion ≈ $1.94 Billion |
+0.60% |
| 2022-12-31 | €1.65 Billion ≈ $1.93 Billion |
+56.93% |
| 2021-12-31 | €1.05 Billion ≈ $1.23 Billion |
-- |
About BIOCYTOGEN PHARMA. H YC1
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides th… Read more